PTCB MTM common mistakes
PTCB MTM · Understand the traps and how to avoid them.
Treating the comprehensive medication review (CMR) and the targeted medication review (TMR) as interchangeable, such as selecting a mailed newsletter or a one-way letter as the answer for 'meeting the CMR requirement.'
Both are 'reviews' performed under the same MTM program, so under time pressure the labels blur, and mailed outreach feels like a legitimate patient contact.
What to do instead
Anchor the distinction with a one-line rule you can recite: the CMR must be an interactive, live, two-way consultation (in person or by phone) with the patient and must be offered at least annually, while a TMR is a focused, medication-specific review that may be one-way. When a stem says 'comprehensive,' look for the two-way interaction in the answer choice.
Swapping the Medication Action Plan (MAP) and the Personal Medication List (PML) - for example, saying the MAP is the complete list of current prescriptions the patient carries.
Both documents are produced at the same CMR encounter, both are patient-facing, and both have generic-sounding names.
What to do instead
Tie each acronym to its function: the PML is a record (what the patient takes, including OTCs, herbals, and supplements, with directions and purpose); the MAP is a plan (what the patient will do, self-management goals, who is responsible, and dates). Ask yourself 'record or plan?' before choosing.
Answering eligibility questions with memorized numeric cutoffs (a specific number of chronic conditions, a specific number of Part D drugs, a specific annual drug-cost figure) that came from an older program year.
Prep material often freezes the figures, and the exact numbers do get referenced casually in practice, so they feel authoritative.
What to do instead
Learn the structure rather than the digits: CMS requires multiple chronic diseases, multiple covered Part D drugs, and an annual cost threshold that CMS sets and updates each year. If a stem hinges on a current-year dollar amount you are not certain of, do not guess the number - reason from the structural criteria and treat the dollar figure as year-specific data to be verified.
Choosing 'change the dose' or 'discontinue the drug' as the final step of an MTM scenario instead of recommending to the prescriber, documenting the recommendation, and scheduling follow-up.
Clinical coursework trains 'identify the problem, then fix it,' so the definitive-sounding clinical action reads as the strongest answer.
What to do instead
Default to the MTM process chain in ambulatory settings: identify the drug therapy problem, formulate a recommendation, communicate it to the prescriber (who authorizes the change), document it in the MAP/PML or note, and follow up to confirm the outcome. Pick a unilateral change only when the stem explicitly puts you in a collaborative practice agreement that grants that authority.
Building a medication list from prescription claims data alone, omitting OTC products, herbal and dietary supplements, samples, and medications filled at other pharmacies.
Claims data is the easiest source to pull and the framer of the scenario hands it to you, so it looks complete.
What to do instead
Treat 'obtain a best possible medication history' as an active, open-ended interview step. Before answering, ask whether the list in the stem includes nonprescription and non-claim items; if a choice adds a structured interview covering OTCs, supplements, samples, and other sources, it is usually the safest answer.
Responding to a described look-alike/sound-alike mix-up or a repeated process failure with 'counsel the patient more carefully' rather than a system-level control such as tall-man lettering, physical separation, barcode verification, or an independent double check.
Patient counseling is the familiar, always-defensible answer, so it wins by default when the error's root cause is not explicitly analyzed.
What to do instead
Diagnose the cause first: if the stem describes a knowledge or adherence gap, choose education; if it describes a system, storage, naming, or workflow hazard, choose the system control. Ask 'would counseling this one patient have prevented this error?' If not, it is the wrong answer.
Assuming a patient is nonadherent from a refill gap or a single late fill without checking the appropriate adherence measure, or confusing proportion of days covered (PDC) with medication possession ratio (MPR) and the 80% threshold.
Anecdotal refill impressions are intuitive, and the two ratio measures are easily treated as synonyms.
What to do instead
Use PDC as the quality measure (days covered divided by days in the measurement period) and remember the common 80% threshold used in adherence quality measures. Before labeling nonadherence, look for a refill-based calculation or a documented reason (cost, side effect, regimen complexity) in the stem; absent data, choose 'assess further' over 'nonadherent.'
Reversing or guessing the direction of cytochrome P450 effects - for example, labeling rifampin as an inhibitor or fluconazole/ketoconazole as inducers of the relevant substrate.
The interaction lists are long and memorized as a blur, and the question may not show the substrate's concentration moving, so there is no built-in feedback.
What to do instead
Classify by direction of effect rather than by memorizing the drug as 'an interaction': inducers lower substrate levels (rifampin, carbamazepine, phenytoin, St. John's wort), inhibitors raise them (azoles, macrolides such as clarithromycin/erythromycin, protease inhibitors, grapefruit). State the direction to yourself before reading the answer choices.
Renal dosing errors from using the wrong estimate or the wrong body weight - for example, dosing by eGFR when the drug's labeling is based on Cockcroft-Gault creatinine clearance, or using total body weight in an obese or low-weight patient without considering an adjusted weight.
eGFR, CrCl, and serum creatinine all appear as 'kidney function' numbers, and calculators silently pick a default weight.
What to do instead
Before calculating, ask three questions: which formula does this drug's labeling specify, what units are given (note that eGFR is normalized to 1.73 m2 body surface area while CrCl is not), and which weight does the chosen equation require. Write the units and the weight basis next to your answer.
Treating drugs within a class as freely interchangeable at equal doses - assuming all statins have equivalent LDL lowering, all proton pump inhibitors are equipotent at the same milligram dose, or that an ARB will reproduce an ACE inhibitor's cough.
Class-level thinking is efficient and is reinforced by formulary 'therapeutic interchange' language, so within-class differences are skipped.
What to do instead
When a stem involves a switch, verify three things before answering: relative potency (statins differ substantially per milligram; PPIs differ in labeled doses), the specific indication and its goal, and whether the adverse effect or benefit is a class effect or molecule-specific. If the answer requires a dose conversion you cannot support, that choice is probably the distractor.